Javascript must be enabled to continue!
Abstract 1285: Deep mutagenesis analysis on BRCA1 variants in high throughput DNA repair assays
View through CrossRef
Abstract
Genetic screening of Hereditary Breast and Ovarian Cancer (HBOC)-associated genes can aid in prevention of the onset of cancer by increased surveillance or preventative surgery if the genetic information is clear. Often, the genetic information is ambiguous since missense substitutions may be common in aggregate but individually these missense variants occur too infrequently for genetic segregation to be conclusive and are known as Variants of Unknown Significance (VUS). One commonly screened HBOC gene is BRCA1, with mutations found in 40-45% of hereditary breast cancer cases. The BRCA1 protein has the critical tumor suppressive function mediating homology-directed repair (HDR), which is used for the repair of double-stranded breaks (DSB) in DNA. Clinical mutant databases, such as ClinVar, contain the clinical classification of BRCA1, but, unfortunately, in many of these databases, most of the variants are classified as VUS or have conflicting data. We suggest that laboratory-based functional analysis can augment the genetic and clinical data, enabling the understanding of whether a specific variant is benign or pathogenic and predisposing to breast and ovarian cancer. We have developed a high-throughput method for analyzing the function of individual missense variants of BRCA1 in the DNA repair process. The goal is to have functional analysis for every possible amino acid substitution in BRCA1, and this will be publicly available for geneticists to consider when evaluating the likelihood of cancer predisposition an individual with a VUS in BRCA1. We have completed analysis of the amino-terminal RING domain, and we will present new results for the carboxy-terminal BRCT domain. We develop a computational pipeline that starts with sequence data from DNA repair assays to obtain a score for each variant. This pipeline will include statistical programs to evaluate the confidence level for these results, which will then be compared to the information provided in the ClinVar database. In summary, this work describes a computational framework for deconvoluting sequencing results of a high-throughput approach to measure the functional impact of each possible missense variant in the BRCT domain of BRCA1.
Citation Format: Mariame Diabate, Alexandrea Adamovich, Tapahsama Banerjee, Michael Freitas, Jeffrey Parvin. Deep mutagenesis analysis on BRCA1 variants in high throughput DNA repair assays [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1285.
American Association for Cancer Research (AACR)
Title: Abstract 1285: Deep mutagenesis analysis on BRCA1 variants in high throughput DNA repair assays
Description:
Abstract
Genetic screening of Hereditary Breast and Ovarian Cancer (HBOC)-associated genes can aid in prevention of the onset of cancer by increased surveillance or preventative surgery if the genetic information is clear.
Often, the genetic information is ambiguous since missense substitutions may be common in aggregate but individually these missense variants occur too infrequently for genetic segregation to be conclusive and are known as Variants of Unknown Significance (VUS).
One commonly screened HBOC gene is BRCA1, with mutations found in 40-45% of hereditary breast cancer cases.
The BRCA1 protein has the critical tumor suppressive function mediating homology-directed repair (HDR), which is used for the repair of double-stranded breaks (DSB) in DNA.
Clinical mutant databases, such as ClinVar, contain the clinical classification of BRCA1, but, unfortunately, in many of these databases, most of the variants are classified as VUS or have conflicting data.
We suggest that laboratory-based functional analysis can augment the genetic and clinical data, enabling the understanding of whether a specific variant is benign or pathogenic and predisposing to breast and ovarian cancer.
We have developed a high-throughput method for analyzing the function of individual missense variants of BRCA1 in the DNA repair process.
The goal is to have functional analysis for every possible amino acid substitution in BRCA1, and this will be publicly available for geneticists to consider when evaluating the likelihood of cancer predisposition an individual with a VUS in BRCA1.
We have completed analysis of the amino-terminal RING domain, and we will present new results for the carboxy-terminal BRCT domain.
We develop a computational pipeline that starts with sequence data from DNA repair assays to obtain a score for each variant.
This pipeline will include statistical programs to evaluate the confidence level for these results, which will then be compared to the information provided in the ClinVar database.
In summary, this work describes a computational framework for deconvoluting sequencing results of a high-throughput approach to measure the functional impact of each possible missense variant in the BRCT domain of BRCA1.
Citation Format: Mariame Diabate, Alexandrea Adamovich, Tapahsama Banerjee, Michael Freitas, Jeffrey Parvin.
Deep mutagenesis analysis on BRCA1 variants in high throughput DNA repair assays [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1285.
Related Results
Abstract 1563: Damage-induced BRCA1 phosphorylation contributes to the timing of end resection
Abstract 1563: Damage-induced BRCA1 phosphorylation contributes to the timing of end resection
Abstract
Germline mutations of BRCA1 predispose women to breast and ovarian cancers. BRCA1 functions as a tumor suppressor. A wealth of evidence has established that...
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract
Objective: The BRCA1 C-Terminal (BRCT) domain of BRCA1 has been found to interact with three accessory proteins (PRR5, RICTOR, and SIN1) of mTOR complex ...
Abstract 1453: Transcriptoma analyses in triple-negative breast cancer with BRCA1 germline mutation
Abstract 1453: Transcriptoma analyses in triple-negative breast cancer with BRCA1 germline mutation
Abstract
Triple-negative breast cancer (TNBC), characterized by lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal grow...
Identification of shared neoantigens in BRCA1-related breast cancer
Identification of shared neoantigens in BRCA1-related breast cancer
Personalized neoantigen-based cancer vaccine has been shown to be safe and immunogenic in cancer patients; however, the manufacturing process can be costly and brings about delay i...
Abstract 5613: Unclassified variants and missense polymorphisms in BRCA1 and BRCA2 genes in Algerian breast/ovarian cancer families
Abstract 5613: Unclassified variants and missense polymorphisms in BRCA1 and BRCA2 genes in Algerian breast/ovarian cancer families
Abstract
Background: BRCA1 and BRCA2 germline mutations predispose heterozygous carriers to hereditary breast/ovarian cancer. Unclassified variants (UVs) and missens...
Abstract A21: Enhancing chemotherapeutic responses in CNS malignancy through suppression of hyperactive DNA damage repair pathways
Abstract A21: Enhancing chemotherapeutic responses in CNS malignancy through suppression of hyperactive DNA damage repair pathways
Abstract
Introduction: We are targeting DNA repair pathways to enhance existing chemoradiotherapeutic strategies against medulloblastoma (MB) and malignant glioma (M...
Estrogen Rececptor (ER)-Positive Breast Cancers in BRCA1 Mutation Carriers: Mutation-Related or Sporadic?
Estrogen Rececptor (ER)-Positive Breast Cancers in BRCA1 Mutation Carriers: Mutation-Related or Sporadic?
Abstract
Background: Most invasive breast cancers (IBC) in BRCA1 mutation carriers are ER negative (-) and have a basal-like phenotype by expression array analysis. ...
Pregnancy Hormone Mediated Tumorigenesis in BRCA1 Defective Breast Cancers
Pregnancy Hormone Mediated Tumorigenesis in BRCA1 Defective Breast Cancers
Background and Objective
BRCA1 mutations predispose to breast and ovarian cancers, the exact reason for the tissue specificity is unknown. The role of hormonal ...

